Category: Portfolio News

Glydways announces $56 Million Series B Round with New Science Ventures, ACS Group, Khosla Ventures and Gates Frontier

Glydways announces $56 Million Series B Round with New Science Ventures, ACS Group, Khosla Ventures and Gates Frontier

Glydways, a leader in developing on-demand Personal Rapid Transit (PRT), has announced its $56 million Series B round, including the conversion of notes valued at more than $28 million and led by New Science Ventures with participation from The ACS Group and Gates Frontier. Khosla Ventures, Glydways first investor, is

Read More
Paragraf named Business of the Year in Cambridge glory parade

Paragraf named Business of the Year in Cambridge glory parade

Paragraf, the first company in the world to mass produce graphene-based electronic devices using standard semiconductors processes, was named Business of the Year in the 33rd annual Business Weekly Awards on 14 September 2023. Co-founders Simon Thomas – the CEO – and CSO Professor Sir Colin Humphreys received the coveted

Read More
Zeotap and Artefact join forces to enhance economic outcomes for enterprises with Customer Data Platform

Zeotap and Artefact join forces to enhance economic outcomes for enterprises with Customer Data Platform

Zeotap CDP, the easy, secure and impactful Customer Data Platform (CDP) has established a strategic partnership with Artefact, a global data consulting service specialist. This collaboration will help to deliver effective data-driven marketing while prioritising consumer privacy and security. Enterprises will benefit from a holistic and integrated approach that will

Read More
VUV Analytics Announces Publication of ASTM D8519-23

VUV Analytics Announces Publication of ASTM D8519-23

VUV Analytics, Inc. is proud to announce the publication of ASTM D8519-23, a groundbreaking new method for the Determination of Hydrocarbon Types in Waste Plastic Process Oil using Gas Chromatography with Vacuum Ultraviolet Absorption Spectroscopy (GC-VUV). This method is the first of its kind, designed to accurately characterize WPPO produced

Read More
Ventyx Biosciences announces initiation of dosing in a Phase 1 trial of VTX3232, a novel CNS-penetrant NLRP3 inhibitor

Ventyx Biosciences announces initiation of dosing in a Phase 1 trial of VTX3232, a novel CNS-penetrant NLRP3 inhibitor

Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, has announced that the first subject has been dosed in a Phase 1 trial of VTX3232, a novel central nervous system

Read More
Ventyx Biosciences announces completion of enrollment of the Phase 2 trial of VTX002 in ulcerative colitis and the Phase 2 trial of VTX958 in plaque psoriasis

Ventyx Biosciences announces completion of enrollment of the Phase 2 trial of VTX002 in ulcerative colitis and the Phase 2 trial of VTX958 in plaque psoriasis

Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, has announced that the Company has completed patient enrollment in the Phase 2 trial of VTX002 in ulcerative colitis and the

Read More
Novadip Biosciences SA announces first pediatric patient with congenital pseudoarthrosis of the tibia undergoes implantation with NVD-003, an autologous tissue regeneration product, in Phase 1b/2a US/EU clinical trial

Novadip Biosciences SA announces first pediatric patient with congenital pseudoarthrosis of the tibia undergoes implantation with NVD-003, an autologous tissue regeneration product, in Phase 1b/2a US/EU clinical trial

Novadip Biosciences SA (“Novadip” or “the Company”), a clinical-stage biopharmaceutical company developing a new class of regenerative tissue products to accelerate healing of large bone defects and injuries in a single treatment, has announced that the first patient has been implanted with its investigational tissue regeneration product, NVD-003, in its

Read More
Trellis Bioscience announces positive interim Phase 1 results for TRL1068, a novel native human monoclonal antibody which reduces bacterial biofilm burden in chronic prosthetic joint infections

Trellis Bioscience announces positive interim Phase 1 results for TRL1068, a novel native human monoclonal antibody which reduces bacterial biofilm burden in chronic prosthetic joint infections

Trellis Bioscience Inc, a clinical stage privately held biotechnology company focused on the discovery and development of native human monoclonal antibodies, has announced a clinical proof-of-concept milestone from a planned interim analysis of the company's Phase 1 trial of its lead antibody, TRL1068 (calpurbatug), in patients with prosthetic joint infections

Read More
Paragraf acquires Cardea Bio to extend graphene electronics leadership

Paragraf acquires Cardea Bio to extend graphene electronics leadership

Paragraf, the only company in the world to mass produce graphene electronics using transfer-free graphene and standard semiconductor processes, has acquired Cardea Bio, the world’s leading producer of graphene-based biocompatible chips. Cardea Bio is to be renamed Paragraf USA and the San Diego facility, team and operations have already become

Read More
VUV Analytics announces $20 million financing

VUV Analytics announces $20 million financing

VUV Analytics, Inc. has announced that it has raised $20 million in equity financing—led by existing investors S3 Ventures and New Science Ventures—bringing its total funding to over $36 million.  The announcement follows the recent launch of the company’s LUMA product and a record year for revenue with its unit

Read More
ProterixBio announces commercial offering of Quantitative Soluble ST2 Assay

ProterixBio announces commercial offering of Quantitative Soluble ST2 Assay

ProterixBio, Inc. has announced the offering of the Presage® ST2 Assay as a testing service through ProterixBio’s high-complexity CLIA laboratory. This Assay has been FDA cleared for use in conjunction with clinical evaluation as an aid in assessing the prognosis of patients diagnosed with chronic heart failure. Heart failure is

Read More
Picocom and Antevia Networks collaborate to provide new innovative 5G in-building solutions for enterprise private networks

Picocom and Antevia Networks collaborate to provide new innovative 5G in-building solutions for enterprise private networks

Picocom, the 5G Open RAN baseband semiconductor and software specialist, has announced Antevia Networks has selected Picocom’s award-winning silicon technology to empower its new innovative 5G in-building solutions. The partnership combines Antevia Networks’ technology with Picocom’s latest generation 5G system-on-chip silicon to drive innovations to address the many challenges of

Read More